Last updated on December 2019

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery


Brief description of study

Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and safety of selexipag in subjects with inoperable or persistent/recurrent CTEPH.

Detailed Study Description

Subjects will be recruited in two sequential cohorts: the first 90 randomized subjects will undergo a right heart catheterization (RHC) with measurement of pulmonary vascular resistance (PVR) at Week 20 and will constitute the hemodynamic cohort; the remaining participants will constitute the non-hemodynamic cohort; they will undergo the same overall study assessments as the hemodynamic cohort excepted for RHC at Week 20.

Clinical Study Identifier: NCT03689244

Find a site near you

Start Over

The Alfred Hospital

Melbourne, Australia
6.21miles
  Connect »